Clinical trials: Glial Tumor
Glioblastoma Multiforme, Relapse
IA Carboplatin + Radiotherapy in Relapsing GBM
Treatment of glioblastoma involves an optimal surgery, followed by a combination of radiation and temozolomide chemotherapy. Progression-free survival (PFS) with this treatment is only 6.9 months and relapse is the norm.
- Trial name
- NCT03672721
- Testing
- IA Carbo+ Radiation
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Université de Sherbrooke
Lymphoma, Childhood Lymphoma
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
Toxicities related to pediatric cancer treatment can lead to significant illness, organ damage, treatment delays, increased health care cost, and decrease in quality of life.
- Conditions
- Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor
- Trial name
- UVA-Gen001 (NCT02624388)
- Testing
- Genistein
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Virginia
Brain Cancer
Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma
To investigate the safety of delivering arsenic trioxide (ATO) in combination with stereotactic radiotherapy in recurrent malignant glioma by performing an open label, Phase I dose escalation trial.
- Trial name
- NCT00185861
- Testing
- Arsenic Trioxide, Stereotactic radiosurgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Glioma Glioblastoma Multiforme
Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma
Phase I open-label trial of 123I-ATT001 monotherapy and in combination with treatment therapies in subjects with relapsed glioblastoma.
- Trial name
- CITADEL-123 (NCT06650605)
- Testing
- 123I-ATT001
- Where
- 2 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Theragnostics Ltd
Brain Tumors
Fluorescence Guided Resection of Brain Tumors
Removing a tumor from your brain is hard to do because, very often, brain tumors do not have boundaries that are easy for your surgeon to find. In many cases, the surgeon can't tell exactly where the tumor begins or ends.
- Trial name
- FGR (NCT00870779)
- Testing
- 5-aminolevulinic acid
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- David W. Roberts
Brain Cancer, Glioblastoma
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
- Conditions
- Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis
- Trial name
- NCT06058988
- Testing
- Trastuzumab deruxtecan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent IDH1/2 Mutated Glioma
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation
Glioma are the most commun frequent brain tumour. Mutation of Isocitrate DeHydrogenase IDH1 or IDH2 genes affect 40% of gliomas, mostly grade II and III gliomas.
- Trial name
- AGIR (NCT03666559)
- Testing
- Azacitidine
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain Stem Gliomas
Antineoplaston Therapy in Treating Patients With Brain Stem Glioma
RATIONALE: Current therapies for a brain stem glioma provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of brain stem gliomas.
- Trial name
- NCT00003459
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Burzynski Research Institute
Breast Cancer, Glioma
A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers
This study will examine, for the first time, the independent contribution of a patient's own genetic makeup to the development of post-radiation complications, permitting the future development of predictive tests to avoid…
- Conditions
- Breast Cancer, Glioma, Prostate Cancer, Carcinoma, Squamous Cell
- Trial name
- NCT00122239
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- AHS Cancer Control Alberta
Adult Diffuse Astrocytoma, Adult Mixed Glioma
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
This trial studies the natural history of brain function, quality of life, and seizure control in patients with brain tumor who have undergone surgery.
- Conditions
- Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Cognitive/Functional Effects
- Trial name
- NCT01417507
- Testing
- cognitive assessment, magnetic resonance imaging, laboratory biomarker analysis
- Where
- 41 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- Radiation Therapy Oncology Group
Astrocytoma, Glioma
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Background: Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months.
- Conditions
- Astrocytoma, Glioma, Recurrent Glioblastoma
- Trial name
- NCT06344130
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors, Meningioma
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
- Trial name
- NCT03273712
- Testing
- 90Y-DOTA tyr3-Octreotide, 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan, Amino Acids
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Iowa
Medulloblastoma, Rhabdomyosarcoma
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in children with recurrent or refractory medulloblastoma, or other…
- Conditions
- Medulloblastoma, Rhabdomyosarcoma, Neuroblastoma, Hepatoblastoma
- Trial name
- NCT01125800
- Testing
- LDE225
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment…
- Conditions
- Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1, Recurrent Visual Pathway Glioma
- Trial name
- NCT01089101
- Testing
- Biospecimen Collection, Selumetinib
- Where
- 17 sites in United States
- Volunteers
- 217 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Gliomas
Short Course of Radiation for Gliomas in Elderly Patients
Patients with high grade brain tumors will be treated to test shortened course of radiation therapy with the use of precise, focused radiation with cyberknife.
- Trial name
- NCT00386919
- Testing
- CyberKnife
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Beth Israel Deaconess Medical Center
Low-grade Glioma, IDH2 Gene Mutation
Niraparib In Recurrent IDH 1/2 Gliomas
This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2 mutant glioma.
- Conditions
- Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma, IDH1 Mutation
- Trial name
- NCT05406700
- Testing
- Niraparib, Resection/Treatment with Niraparib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Glioblastoma, Radiotherapy
Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy
No predictive factors are known for the response to the bevacizumab anti-angiogenic molecule (Avastin) given in the event of relapse of glioblastoma (GBM) following radiochemotherapy.
- Conditions
- Glioblastoma, Radiotherapy, Chemotherapy
- Trial name
- SPECTROBEVA (NCT03144167)
- Testing
- Analysis of spectroscopic biomarkers of proliferation for six-month survival
- Where
- France
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Neuroendocrine Tumors, Carcinoid Tumors
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
- Trial name
- GA-68 (NCT01619865)
- Testing
- 68Ga-DOTATOC PET/CT
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Sue O'Dorisio
Glioma, Fear of Cancer
FearLess in Cognitively Intact Patients With Glioma
This study will assess the preliminary feasibility and acceptability of FearLess, a newly-developed psychological intervention for fear of cancer recurrence (FCR) among cognitively-intact patients with glioma.
- Trial name
- FearLess (NCT05604365)
- Testing
- FearLess Intervention
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Glioblastoma
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
This is a pilot study to determine the efficacy and safety of aldoxorubicin in subjects with glioblastoma who have progressed following surgery and prior treatments.
- Trial name
- NCT02014844
- Testing
- 250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- ImmunityBio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.